002750 Kunming Longjin Pharmaceutical
- 2.09
- +0.10+5.03%
Kunming Longjin Pharmaceutical News
*ST Longjin: 2024 Semi-Annual Report Summary
*ST Longjin: 2024 Semi-Annual Report
ST Longjin (002750.SZ): Net loss of 4.224 million yuan in the first half of the year.
Geelong reported its semi-annual report for 2024 on August 27th. The report shows a revenue of 39.4178 million yuan for the reporting period, a decrease of 9.66% year-on-year. The net income attributable to the company's shareholders is -4.224 million yuan, with a narrowed loss year-on-year. The net income attributable to the company's shareholders after deducting non-recurring gains and losses is -11.4206 million yuan. The basic earnings per share is -0.0105 yuan.
ST Longjin (002750.SZ) released its performance for the first half of the year, with a net loss of 4.224 million yuan.
*ST Longjin (002750.SZ) released its 2024 semi-annual report, during the reporting period, the company achieved operating income...
Special treat Longjin (002750.SZ): As of August 9, the number of shareholders in the company was 38,065.
On August 14th, Gelunhui reported that as of the latest date of August 9, 2024, the number of shareholders in Special Treat Longjin (002750.SZ) was 38,065.
Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 37%
Kunming Longjin Pharmaceutical: 2024 Interim Performance Forecast
*Special Treat Longjin (002750.SZ): Expected to lose between 3.6 million yuan and 4.9 million yuan in the first half of the year.
On July 10th, Gelunhui reported that *ST Longjin (002750.SZ) announced its performance forecast for the first half of 2024, with a net loss of 3.6 million yuan to 4.9 million yuan attributable to shareholders of the listed company, compared with a loss of 15.7777 million yuan in the same period last year. After deducting non-recurring gains and losses, the net loss was 9.7 million yuan to 13.15 million yuan, compared with a loss of 19.4725 million yuan in the same period last year. The basic earnings per share were expected to be between a loss of 0.0090 yuan/share and a loss of 0.0122 yuan/share. Due to the continued impact of policy factors such as medical insurance payment restrictions, hospital prescription restrictions, and the company's injection of scutellaria baicalensis extract price reduction by 67%.
Longjin Pharmaceutical (002750.SZ): Net loss of 4.4918 million yuan in the first quarter
Gelonghui, April 29 | Longjin Pharmaceutical (002750.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 26.3884 million yuan, up 22.43% year on year; net profit attributable to shareholders of listed companies was 4.4918 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.1091 million yuan; basic earnings per share - 0.0112 yuan.
More Unpleasant Surprises Could Be In Store For Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) Shares After Tumbling 29%
Here's Why We're Not Too Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Situation
Longjin Pharmaceutical (002750.SZ): Lixing Industrial plans to reduce its holdings by no more than 3%
Gelonghui, March 12 | Longjin Pharmaceutical (002750.SZ) announced that the shareholder Lixing Industrial Co., Ltd. (“Lixing Industrial”) plans to reduce the company's shares by no more than 12,015,000 shares (accounting for 3% of the company's total share capital) through centralized bidding and bulk transactions. Among them, holdings were reduced by no more than 4,005,000 shares (1% of the company's total share capital) through centralized bidding, within three months after 15 trading days from the date of disclosure of this announcement.
Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Longjin Pharmaceutical (002750.SZ): As of February 29, 2024, the number of shareholders of the company was 57,979
Gelonghui March 4 | Longjin Pharmaceutical (002750.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was 57,979.
Longjin Pharmaceutical (002750.SZ): Stock trading may be subject to delisting risk warning
Longjin Pharmaceutical (002750.SZ) issued an announcement. According to preliminary estimates by the company's finance department, it is expected that the 2023 fiscal year will...
Kunming Longjin Pharmaceutical (SZSE:002750) One-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Surges 21% This Past Week
Longjin Pharmaceutical (002750.SZ): Pre-loss of 63 million yuan to 82 million yuan in 2023
Gelonghui, January 29丨Longjin Pharmaceutical (002750.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 63 million yuan to 82 million yuan, loss of 56,165 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 73 million yuan to 92 million yuan, loss of 57.344 million yuan for the same period last year; basic earnings loss per share of 0.1,573 yuan/share to 0.2047 yuan/share; operating income of 81 million yuan to 99 million yuan per share After-sales Revenue of 75 million yuan to 9
[BT Financial Report Momentary Analysis] Longjin Pharmaceutical's 2023 Quarterly Report: Market Performance with Challenges and Opportunities
Kunming Longjin Pharmaceutical Co., Ltd. (stock code: 002750), since its establishment in 1996, has focused on R&D, production and sales of modern proprietary Chinese medicines and high-end chemical generic drugs. As a national high-tech enterprise, Longjin Pharmaceutical has taken a place in the treatment of cardiovascular and endocrine diseases with many domestic and foreign invention patents. The company's sales strategy, which is guided by clinical value and centered on academic promotion, has successfully expanded to thousands of medical institutions across the country. In terms of assets and liabilities, Longjin Pharmaceutical's 2023 three-quarter report shows that the company's total assets were 683 million yuan, compared to the end of the previous year
Longjin Pharmaceutical (002750.SZ): As of January 10, 2024, the number of shareholders of the company was 57,899
Gelonghui January 16 | Longjin Pharmaceutical (002750.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 57,899.
Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) Share Price Not Quite Adding Up
Analysis
Price Target
No Data
